• Sicheng He, Wei Lu, Xun Ding, Jun Zhou, Di Liu, Yang Zhu, Fugang Yang, and Zanmei Fu.
• The Interventional Diagnostic and therapeutic Center, Zhongnan Hospital of Wuhan University, Wuhan, China.
• Medicine (Baltimore). 2024 Mar 15; 103 (11): e37513e37513.

BackgroundWhile papillary thyroid carcinoma (PTC) generally exhibits a favorable prognosis post-surgery, the poorly differentiated subtype presents elevated rates of postoperative recurrence. Certain aggressive cases demonstrate invasive behavior, compromising adjacent structures and leading to a poor prognosis. This study delineates a unique case of postoperative PTC recurrence, complicated by esophageal fistula, that showed favorable outcomes following brief Vemurafenib treatment.Patient DescriptionA 64-year-old female patient underwent surgical resection for PTC, subsequently experiencing rapid tumor recurrence and development of an esophageal fistula.DiagnosisThe patient was confirmed to have locally advanced PTC through intraoperative cytopathology. The cancer recurred postoperatively, culminating in the formation of an esophageal fistula.MethodsThe patient was administered Vemurafenib at a dosage of 960 mg twice daily following tumor recurrence.ResultsA 12-month regimen of targeted Vemurafenib therapy led to a substantial reduction in tumor size. Concurrently, the esophageal fistula underwent complete healing, facilitating successful removal of the gastrostomy tube. The tumor response was classified as stable disease.Conclusion SubsectionsVemurafenib demonstrates potential as a targeted therapeutic strategy for recurrent PTC harboring the BRAFV600E mutation. This approach may effectively mitigate tumor dimensions and the associated risk of esophageal and tracheal fistulas.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

22 keywords...

hide…